6653-80-1

Basic information

• Product Name: 1-(CHLOROMETHYL)-4-ETHOXYBENZENE
• Synonyms: Benzene, 1-(chloromethyl)-4-ethoxy-
• CAS NO: 6653-80-1
• Molecular Formula: C₉H₁₁ClO
• Molecular Weight: 170.64
• Mol File: 6653-80-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 246.5°C at 760 mmHg
• Flash Point: 107.2°C
• Appearance: /
• Density: 1.082g/cm³
• Vapor Pressure: 0.0426mmHg at 25°C
• Refractive Index: 1.512
• CAS DataBase Reference: 1-(CHLOROMETHYL)-4-ETHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(CHLOROMETHYL)-4-ETHOXYBENZENE(6653-80-1)
• EPA Substance Registry System: 1-(CHLOROMETHYL)-4-ETHOXYBENZENE(6653-80-1)

Safety Data

• Hazardous Substances Data: 6653-80-1(Hazardous Substances Data)

Usage

General Description

1-(Chloromethyl)-4-ethoxybenzene is a chemical compound with the molecular formula C9H11ClO. It is an aromatic compound that contains a benzene ring with a chloromethyl group and an ethoxy group attached. 1-(CHLOROMETHYL)-4-ETHOXYBENZENE is used as a building block in organic synthesis and can be used to create a variety of other chemicals. It may also have applications in the pharmaceutical and agrochemical industries. This chemical has properties that make it potentially hazardous, and proper precautions should be taken when handling and using it.

InChI:InChI=1/C9H11ClO/c1-2-11-9-5-3-8(7-10)4-6-9/h3-6H,2,7H2,1H3

Upstream product

• 622-60-6 1-ethoxy-4-methylbenzene 
• 106-44-5 p-cresol 
• 10031-82-0 4-ethoxybenzaldehyde 
• 50-00-0 formaldehyd 
• 103-73-1 Phenetole 
• 6214-44-4 4-ethoxybenzyl alcohol 

Downstream Products

• 69743-35-7 (4-ethoxybenzyl)triphenylphosphonium chloride 
• 1224715-24-5 N-(1-{5-[(4-ethoxybenzyl)sulfanyl]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224715-36-9 N-(1-{5-[(4-ethoxybenzyl)oxy]-1H-benzimidazol-2-yl}ethyl)acetamide 
• 1224715-01-8 N-(1-{5-[(4-ethoxybenzyl)oxy]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224715-00-7 N-(1-{5-[(4-ethoxybenzyl)oxy]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224714-82-2 N-(1-{6-[(4-ethoxybenzyl)oxy]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224716-81-7 2-{6-[(4-ethoxybenzyl)oxy]-1-benzofuran-3-yl}propanoic acid 
• 1224716-80-6 methyl 2-{6-[(4-ethoxybenzyl)oxy]-1-benzofuran-3-yl}propanoate 
• 1224714-91-3 N-(1-{5-[(4-ethoxybenzyl)oxy]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224714-79-7 N-(1-{6-[(4-ethoxybenzyl)oxy]-1,2-benzisoxazol-3-yl}ethyl)acetamide 
• 1224714-74-2 N-(1-{6-[(4-ethoxybenzyl)oxy]-1-benzofuran-3-yl}ethyl)acetamide 
• 1224715-26-7 N-(1-{5-[(4-ethoxybenzyl)sulfinyl]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224715-25-6 N-(1-{5-[(4-ethoxybenzyl)sulfonyl]-1-benzofuran-2-yl}ethyl)acetamide 
• 1224716-79-3 methyl {6-[(4-ethoxybenzyl)oxy]-1-benzofuran-3-yl}acetate 

Relevant articles and documents

In vitro study and structure-activity relationship analysis of stilbenoid derivatives as powerful vasorelaxants: Discovery of new lead compound

The development of vasorelaxant as the antihypertensive drug is important as it produces a rapid and direct relaxation effect on the blood vessel muscles. Resveratrol (RV), as the most widely studied stilbenoid and the lead compound, inducing the excellent vasorelaxation effect through the multiple signalling pathways. In this study, the in vitro vascular response of the synthesized trans-stilbenoid derivatives, SB 1-8e were primarily evaluated by employing the phenylephrine (PE)-precontracted endothelium-intact isolated aortic rings. Herein we report trans-3,4,4′-trihydroxystilbene (SB 8b) exhibited surprisingly more than 2-fold improvement to the maximal relaxation (Rmax) of RV. This article also highlights the characterization of the aromatic protons in terms of their unique splitting patterns in 1H NMR.

Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-Trisacetic Acid (DO3A)-Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent

We report the synthesis of a macrocyclic Gd chelate based on a 1,4,7,10-Tetraazacyclododecane-1,4,7-Trisacetic acid (DO3A) coordinationn cage bearing an ethoxybenzyl (EOB) moiety and discuss its use as a T1 hepatobiliary magnetic resonance imaging (MRI) contrast agent. The new macrocyclic liver agent shows high chelation stability and high r1 relaxivity compared with linear-Type Gd chelates, which are the current clinically approved liver agents. Our macrocyclic, liver-specific Gd chelate was evaluated in vivo through biodistribution analysis and liver MRI, which demonstrated its high tumor detection sensitivity and suggested that the new Gd complex is a promising contrast agent for liver cancer imaging.

BICYCLIC COMPOUND

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.